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Recent advances in recombinant adeno-associated virus vector transient transfection production, relies on the use of
production. Adeno-associated virus (AAV) is a replication- plasmid DNA transfection to introduce required AAV
defective parvovirus that is being developed as a vector for production components into human cell lines. The sec-human gene transfer. Recombinant AAV (rAAV) vectors are
ond approach focuses on the use of stable rAAV pro-being proposed as a gene transfer vehicle for an array of human
ducer cell lines for the large-scale production of rAAV.diseases. The recent interest in rAAV has been driven by the
unexpected finding that these simple vectors can efficiently Transient transfection is amenable to higher throughput,
transduce a variety of postmitotic cells, resulting in long-lived, allowing the investigator more flexibility to generate and
robust gene expression. However, a major obstacle to common- test multiple rAAV vector constructs. It is hampered byplace usage of rAAV vectors was the production in sufficient
the requirement for the transfection of large numbersquantities for preclinical and human trials. Fortunately, several
of mammalian cells in culture. Conversely, although sta-recent technological advances in vector production, purifica-
tion, and titration have resulted in significant increases (10- ble cell line approaches are readily scaleable, they are
fold) in production capacity. Thus, there are several methods less flexible with regards to the number of vectors that
for the production of rAAV in excess of 104 particles/cell, levels can be rapidly generated and assayed. Both production
that should permit widespread use of this technology for clinical
methods require three essential components for rAAVapplications.
production. The first element is the rAAV vector, which
is a transgene expression cassette flanked by AAV in-
verted terminal repeats (ITRs). The AAV ITRs are lo-Interest in recombinant adeno-associated virus vectors
cated at the ends of the AAV genome and contain all of(rAAV) has steadily increased because of the ability of
the cis sequence information necessary for vector DNAthis vector to mediate long-term, robust in vivo gene
replication and encapsidation [2, 3]. Thus, rAAV vectorsexpression in numerous nondividing cell types (i.e., hepa-
contain only a very small proportion (6%) of the wild-tocytes, neurons, and skeletal myocytes). Efficient in vivo
type AAV genome and lack all viral coding sequences.gene transfer via rAAV transduction requires reason-
Second, the two AAV genes (rep and cap), which encodeably high multiplicities of infection, estimated between
replication and AAV structural proteins, are expressed103 to 105 DNA-containing particles per cell, depending
in trans. The physical separation of these genes and theon the cell type targeted. Moreover, based on large ani-
ITR packaging signal is critical for avoiding the forma-mal studies, a clinical dose in humans will require 1012
tion of wild-type AAV. The rep gene possesses two pro-to 1014 rAAV vector particles, depending on the level
moters (p5 and p19) from which 4 Rep proteins areof therapeutic protein expression needed for treatment
expressed (Rep78, Rep68, Rep52, and Rep40). The p5efficacy [1]. Therefore, the ability to produce high-titer
derived Rep proteins (Rep78 or Rep68) are essential forrAAV is critical for clinical applications and has histori-
rAAV replication. Three capsid proteins (VP1, VP2, andcally been the primary impediment to the widespread
VP3) are synthesized following transcription from theuse of this vector system. This review discusses the recent
rep-inducible p40 cap gene promoter. Finally, becauseadvances in vector production technology that have re-
AAV and recombinant derivatives are replication defec-sulted in the routine isolation of 104 recombinant viral
tive, these viruses require helper virus gene productsparticles per cell. The vast majority of rAAV is produced
from adenovirus or herpesvirus for efficient viral pro-in one of two ways. The first method, referred to as
duction. The helper virus (or specific helper virus genes)
provides a favorable intracellular milieu for robust
Key words: rAAV production, AAV, stable cell lines. rAAV replication and viral synthesis. A schematic of
both production strategies is shown in Figure 1. 2002 by the International Society of Nephrology
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Fig. 1. rAAV production schematic. The top
half of the figure depicts rAAV production via
transient transfection. The process involves the
cotransfection of a rep-cap–containing plas-
mid and an rAAV vector plasmid containing
the AAV ITRs (arrowheads) flanking a gene
expression cassette [promoter (pr), desired
transgene (tg), and polyadenylation signal
(pA)]. Helper functions for efficient rAAV
synthesis are supplied by adenovirus infection
or an adenovirus helper plasmid containing
the VA, E2A, E4 genes. The lower portion
of the figure depicts rAAV production using
stable cell line approaches. Generally, HeLa
cells containing integrated rep-cap and/or
rAAV vector sequences are infected with ei-
ther adenovirus or recombinant HSV to pro-
vide the needed helper functions. rAAV is
then rapidly purified from crude cellular ly-
sates using affinity chromatography (antibody
or heparin sulfate).
ADVANCES IN TRANSIENT early CMV promoter/enhancer (CMV IE)] in place of
the endogenous p40 cap gene promoter [4]. They alsoTRANSFECTION PRODUCTION
observed that overexpression of the Rep78 protein (us-rAAV is most commonly generated in cell culture by
ing the RSV promoter) resulted in reduced capsid pro-co-transfecting 293 or 293T cells with a rAAV vector plas-
tein production. The authors suggested that Rep78 exertsmid and an AAV rep-cap plasmid followed by helper
its negative effect on cap expression by translationaladenovirus infection. Yields of between 102 to 103 viral
repression of capsid mRNA. Moreover, the finding thatparticles per cell are typical using an optimized calcium
a minimum threshold level of capsid protein is necessaryphosphate coprecipitation method. For purposes of clar-
for efficient intranuclear AAV-2 virion formation addedity, all references to rAAV particles, unless otherwise
further support to the conclusion that capsid proteinindicated, assume that these are DNA-containing parti-
levels can be a limiting element in rAAV productioncles. Unfortunately, this method of production is inher-
[12–14]. Li et al also observed that overexpression ofently inefficient because of the requirement for three
Rep78 protein correlated with decreased capsid proteinseparate “hits” on a cell to produce rAAV (cotransfec-
levels, reduced rAAV genome replication, and rAAVtion of two plasmids plus infection with adenovirus) and
titers [6]. Conversely, when the authors downmodulatedis difficult to perform reproducibly on a large scale. How-
Rep78/68 expression (by using a nonconsensus ACG
ever, three recent observations have resulted in10-fold
start codon), they observed increased capsid protein pro-
increases in vector yields. The first was the recognition duction and rAAV yields by approximately 10-fold. Us-
that below a threshold level, AAV-2 capsid protein levels ing a similar strategy, Grimm et al achieved low level
can limit rAAV production [4]. Second, downmodula- Rep expression by using the mouse mammary tumor
tion of Rep78 protein expression results in increased virus LTR promoter (under non-induced conditions) in
capsid protein synthesis and rAAV production [4–7]. place of the native p5 rep promoter [7]. These authors
Finally, by introducing the necessary adenovirus helper also observed increased capsid and rAAV production
genes into cells via plasmid DNA transfection rather (by a factor of 10-fold). How high-level Rep78 expression
than by standard adenovirus infection, moderate in- acts to reduce capsid expression and vector yields in the
creases in rAAV yields are possible [7–12]. Importantly, transient production schema is not completely under-
the resulting rAAV preparations were free of contami- stood, but because the AAV Rep proteins have pleiotro-
nating infectious adenovirus and most adenovirus struc- pic effects on cellular and AAV gene expression, tightly
tural proteins. Vincent et al observed that transient trans- regulated Rep expression appears necessary for optimal
fection vector yields could be increased approximately rAAV titers. For example, Rep78/68 has been shown to
10-fold if AAV capsid expression levels were increased inhibit cap mRNA translation, but these same proteins
are required for efficient cap mRNA transcription fromusing a strong constitutive promoter [human immediate
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the native p40 promoter. Additionally, elevated Rep78/68 STABLE CELL LINE PRODUCTION
expression can repress adenovirus replication and inhibit In addition to transient transfection strategies, there
adenovirus helper functions, resulting in reduced rAAV are several methods currently in use for the large-scale
production capacity. Thus, although clearly needed for production of rAAV using packaging cell lines [16–21].
AAV replication and transcriptional activation, excess In 1990, Vincent et al demonstrated that a cell line ex-
Rep78 levels appear deleterious to efficient rAAV for- pressing rep and cap could be used to package rAAV;
mation. Regardless of the molecular mechanism, the use however, the method still relied on transfection of the
of these downmodulated rep expression plasmids has rAAV genome into the cell line, and reported titers
resulted in increased rAAV production. The third sig- were low [22]. Recently, we and others have developed a
nificant advancement in transient rAAV vector produc- simplified method for generating rAAV based on stable
tion was the development of helper virus-free packaging HeLa cell lines containing integrated copies of the AAV
systems that use a DNA plasmid to supply all helper rep-cap genes and a rAAV vector [16, 17]. To generate
adenovirus functions but is incapable of generating infec- rAAV, the cells are simply infected with wild-type ade-
tious adenovirus. Earlier work defined five adenovirus novirus, which results in the induction of the p5 rep
gene regions that were required for complete helper promoter. rAAV producer cell lines are initially isolated
functions for wild-type and rAAV synthesis (E1, E2, by first cloning the desired cDNA sequence into a rAAV
VA I/II RNA, and E4). Subsequent research refined the vector plasmid. Also present on the same plasmid (or a
minimal set to E1a, E1b, VA I/II RNA, E2A, and E4 separate plasmid) is a selectable marker gene and the
ORF6 [11]. Although this approach added a third plas- native rep-cap helper genes [16, 17]. Following HeLa
mid to the transfection mixture, rAAV yields were equal cell transfection, stable cell lines are screened for viral
to or higher than vector stocks produced by standard production by adenovirus infection and yields quanti-
adenovirus infection. Among the numerous variations, tated by polymerase chain reaction (PCR) or dot blot
Xiao et al reported the generation of a miniadenovirus hybridization [23]. Depending on the producer cell line,
genome plasmid termed pXX6, which deleted several yields between 4 103 to 2 104 particles/cell are typical.
adenovirus structural genes and the MLP promoter [9]. Importantly, recombinant virus generated in this manner
When cotransfected into 293T cells, the authors reported appears free of replication competent wild-type-like
an approximately threefold increase in vector yield over AAV (1 IU of wild-type-like AAV/1011 rAAV particles).
adenovirus infection. Similarly, Matsushita et al also A variation on this basic approach is to infect a stable
found that adenovirus gene transfection resulted in vec- rep-cap expressing HeLa cell line (C12 or B50) with a
tor particle yields that were four times higher than ade- recombinant adenovirus harboring a rAAV vector ge-
novirus infection [11]. Two groups have combined the nome in the adenovirus E1 region [18, 20, 24, 25]. Co-
rep-cap and adenovirus helper genes on a single plasmid infection with wild-type adenovirus is also required to
and reported 10-fold increases in rAAV yields [7, 10]. supply the missing E1 helper gene products. Upon co-
Elevated rAAV yields may be due to the absence of infection, the rAAV vector is excised from the adenovi-
competition between two concurrent viral infections rus genome, replicated, and packaged into infectious viri-
(rAAV and adenovirus) for the host cell macromolecular ons. The primary advantage of this strategy is that
synthesis machinery. Clearly, the major benefit of this repeated stable cell line selection is not necessary and
approach is the complete removal of contaminating ade- reported rAAV yields were between 104 to 105 rAAV
novirus (and most structural proteins) that could dele- particles/cell [20]. Another potential strategy would be
teriously affect rAAV-mediated transgene expression to generate a second recombinant adenovirus containing
through host immune activation. An important question the AAV rep-cap genes; fortunately, such a vector has
is whether all five gene products are necessary for high- been isolated recently (Note added in proof). Interest-
level rAAV production. When using the native rep-cap ingly, human herpes virus type 6 contains a functional
promoters for rAAV production, it appears that all five rep gene homologue [26], and HSV amplicon vectors
genes contribute to optimal rAAV yields [11]. Interest- that carry and express the AAV Rep proteins in a stable
ingly, when the rep and cap gene products were ex- manner have been reported [27, 28]. This has led to the
pressed by constitutive promoters (the mouse metallo- development of a novel stable cell line production system
thionein gene 1 and CMV promoters, respectively), only based on a recombinant herpes simplex virus type I vec-
the E4 ORF6 adenovirus protein appeared necessary for tor (rHSV-1) carrying the AAV rep-cap genes (d27.1-rc)
high-level rAAV production in 293 cells [15]. Thus, un- [21]. In this production scheme, rHSV d27.1-rc provides
der the appropriate rep and cap conditions, it appears complete helper functions for rAAV production. More-
that only the E1 region and the E4 ORF6 protein are over, d27.1-rc is itself replication defective because it
required for rAAV production. A summary of the vari- does not produce a required herpes protein (ICP27) and,
therefore, can only be grown in the appropriate comple-ous rAAV production methods is shown in Table 1.
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menting cell line. Infection of a stable cell line containing plasmids. Vector yields of 104 rAAV particles per cell
were reported. A rep-cap amplification strategy was alsoan integrated rAAV genome with d27.1-rc resulted in
developed using a stable HeLa cell line system, whichvector yields of 104 particles per cell. It is notable that
permitted inducible amplification (4-fold) of integratedto date all stable cell line production methods rely on
rep-cap sequences from a nearby SV40 origin of replica-viral infection to supply helper gene products, and there-
tion using a doxycycline activated SV40 T antigen genefore, the potential for contamination of rAAV vector
cassette [31]. Viral yields of 104 particles per cell werestocks with helper virus or associated viral proteins re-
also reported. Recently, adenovirus inducible rep-capmains a cause for concern. Clearly, improved purification
gene amplification was also documented in stable, HeLamethods (discussed later here) have alleviated many of
rAAV producer cell lines by two groups [32, 33]. Quanti-these concerns, but the development of stable packaging
tative PCR documented episomal rep-cap gene amplifi-cells that supply all rAAV helper functions remains an
cation of approximately 100-fold in response to adeno-important goal for future production strategies. As with
virus infection, which corresponded to rep-cap copyall stable cell line methods, the process is scaleable. Cur-
numbers of approximately 400 to 500 per cell. This obser-rently, several groups are using microcarrier beads, spin-
vation provides a plausible mechanism by which stablener cells, or adherent cell bioreactors (Corning Cell Cube,
HeLa producer cell lines produce high levels of rAAVActon, MA, USA; or Nunc Cell Factory, Rochester, PA,
even though the initial AAV rep-cap copy number is lowUSA) for the growth of 1010 to 1011 producer cells. As-
(typically 5 to 10 copies per cell). Curiously, adenovirus-suming rAAV particle per cell yields of 104, stable cell
inducible rep-cap gene amplification was not observedline approaches can yield between 1014 to 1015 rAAV
when the rep-cap–containing plasmid was transientlyparticles per large-scale preparation.
transfected into HeLa cells, indicating that a dramatic
difference exists in the amplification potential of trans-
RAAV PRODUCTION USING REP-CAP fected rep-cap sequences versus stably integrated se-
GENE AMPLIFICATION quences. In conclusion, there are multiple, viable meth-
ods for the production of rAAV in excess of 104 particlesThe wild-type AAV genome (rep-cap genes) is repli-
per cell. These production levels should permit the wide-cated to 106 copies per cell, of which a significant pro-
spread use of this technology for clinical applicationsportion is in a double-stranded, transcriptionally active
(Table 1).conformation. Thus, a logical goal for rAAV produc-
tion systems is to mimic as closely as possible wild-type
AAV-2 rep-cap gene amplification as it occurs during VECTOR PURIFICATION
a productive infection. Accordingly, it has been docu- Another significant advance in rAAV vector technol-
mented that the transfection of additional rep-cap plas- ogy has been the recent development of several refined
mid copies relative to the rAAV vector plasmid augments chromatography-based purification methods that render
rAAV yields proportionally [28]. Several production sys- traditional isopycnic CsCl gradient purification methods
tems have been reported that allow for varying levels of obsolete [7, 23, 34]. Importantly, vector purity, biological
rep-cap gene amplification, although no system to date potency, and process throughput are all increased using
approaches wild-type levels. The initial report placed a these chromatographic methods. All three methods allow
simian virus 40 (SV40) origin of replication on an AAV for one-day vector purification from clarified cell lysates
rep-cap plasmid. This helper plasmid was electroporated in volumes in excess of 1 L. One method uses an immu-
into COS cells (SV40 T-antigen expressing African green noaffinity approach, whereby a monoclonal antibody
monkey cells) in an attempt to achieve episomal rep-cap (A20) that recognizes a conformational epitope on the
gene amplification via SV40 ori/T-antigen interaction. intact viral particle is coupled to a sepharose resin. Viral
However, low viral yields were reported (1000 particles purification is achieved by a single pass of a crude cell
per cell), and it was unclear whether rep-cap amplifica- lysate containing rAAV, followed by washing and viral
tion was actually achieved in this system [29]. Limited rep- elution with 2.5 mol/L MgCl2. Percent recoveries of 70%
cap gene amplification was also reported using an HSV were reported, and vector preparations contained low
amplicon system [30]. In this production system, the AAV levels (20%) of contaminating cellular proteins [7].
rep-cap genes and rAAV vector sequences were incorpo- The other two approaches use heparin sulfate (a recently
rated into HSV amplicon plasmids that contained the HSV identified co-receptor for AAV-2) as an affinity ligand
origin of replication and packaging signal (oriS-pac). Upon for viral purification. Clark et al reported a single-pass,
transfection, the plasmids were amplified by infection crude lysate purification procedure using a commercial
with a replication defective HSV helper virus (glycopro- heparin sulfate resin (HE POROS; Applied Biosystems,
tein H deleted). This virus supplied both helper rAAV Foster City, CA, USA) and column elution with a linear
salt gradient [23]. Recoveries were on average 70%functions and replicative ability to the HSV amplicon
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Table 1. Estimated rAAV DNase resistant particle per cell yields of several production methods
Producer cell Particles/cella Helper function Rep-cap element Features Ref.
Transient transfection
CaPO4 co-txn 293/293T 1,000 wt Ad infection native rep-cap genes [3]
pDG 293 15,000b Ad mini-plasmid MMLVp rep gene rep downmodulation, wt [7]
AAV free
MTrep & CMVcap 293 10,000 Ad 5 E4 ORF6 mouse metallothionein rep downmodulations, split [15]
rep gene rep-cap helper, wt AAV free
pXX2 293T 100,000 Ad mini-plasmid ACG rep start codon rep downmodulation, dual p5 [9]
promoter element
pVAE2AE4-5 293 13,300c Ad mini-plasmid native rep-cap genes [11]
pSH3/pSH5 293 13,600 Ad mini-plasmid native rep-cap genes combined Ad and rep-cap genes [10]
on a single plasmid
HSV amplicons BHK 28,000e HSV-1 (gH-/TK-) native rep-cap genes rep-cap gene amplification [30]
pspRC 293 12,500d Ad plasmid native rep-cap genes [12]
Cell lines HeLa (B50) 55,000 rAd (E1 deleted) and 5 copies of native rep- order of infection critical for [20]
B50/rAd Ad coinfection cap genes integrated high titer production
pTp HeLa 40,000 wt Ad infection 5–20 copies of rAAV rep-cap gene amplification [23]
vector and rep-cap genes
d27.1-rc 293 24,000f rHSV (ICP27 deleted) native rep-cap genes rHSV provides all rAAV helper [21]
functions
TtetA2 HeLa 29,000 wt Ad infection native rep-cap genes with SV40ori/Tantigen mediated rep- [19]
SV40 ori cap gene amplification
a rAAV DNase resistant particle/cell values were calculated based on the total cell number used to prepare the rAAV stock
b Authors reported 150 replication units per cell; above value was estimated by using a conservative conversion factor of 100 DNase resistant particles per replication
unit
c Authors reported 100 lacZ functional units per cell using plasmid pVAE2AE4-5, and a particle to functional unit ratio of 133
d Authors reported a maximal yield of 5  1012 rAAV particles from 25  15 cm dishes (calculation assumes 1.6  107 cells per dish  25  4  108 293 cells
total)
e Authors reported a maximal yield of 280 GFP transducing units per cell and a ratio of 1:100 for GFP transducing units:DNase resistant particles
f Authors reported a maximal yield of 480 C12 replication units per cell (calculation assumes a conversion factor of 1 C12 RU:50 DNase resistant particles)
with purity in excess of 95%. Column capacity (1.4 mL aration are devoid of DNA [23, 35]. Accordingly, this
may imply that the efficiency of rAAV genome encapsi-bed volume) was 1014 DNA-containing particles. A
dation may be a rate-limiting step in infectious rAAVsecond method also used the HE POROS resin after
formation. (2) The second method determines the num-partial rAAV purification using the iso-osmotic gradient
ber of Dnase-resistant vector genomes (encapsidated vi-reagent Iodixanol [34] and reported viral recoveries and
ral genomes) present in the rAAV vector stock. Briefly,purity similar to Clark et al. All three methods appear
to derive this value, a rAAV vector preparation is treatedto produce lower rAAV particle:infectious particle ratios
with DNase to degrade residual nonencapsidated vector(100:1) than that observed using CsCl purification. Im-
genomes. The DNase is inactivated by proteinase Kportantly, all three methods greatly decrease the level
treatment, and the remaining viral nucleic acid quanti-of contaminating cellular and helper virus proteins and
tated by PCR or dot blot hybridization and comparedresult in a product that is of sufficient purity for clinical
with a known plasmid DNA standard curve. The advan-testing.
tage to this particle titer determination is that using quan-
titative PCR, titers can be rapidly generated in four hours
VECTOR TITRATION [23]. Moreover, comparable Dnase-resistant genome ti-
The lack of a single method for determining the titer ters can be derived for all vector preparations, regardless
of rAAV stocks has led to some confusion in the field. of the transgene or promoter used in the construct. (3)
Essentially, rAAV can be measured in four ways: (1) A A third method, also applicable to all vector stocks, de-
physical particle titer enumerates the total number of termines the proportion of viral particles that can infect
viral particles (whether containing DNA or not) present and replicate in a target cell line. This method, commonly
in a rAAV preparation. A particle titer can be deter- referred to as a replication center assay, determines the
mined by EM, a commercial A20 antibody-based en- number of infectious units in a rAAV preparation by
zyme-linked immunosorbent assay (ELISA) [35] or can intracellular amplification of the rAAV genome in the
be calculated using the known molecular mass of AAV-2 presence of wild-type AAV and adenovirus [36]. Detec-
and the protein concentration of a highly purified vector tion of rAAV replication foci is accomplished by filter
stock (1.5  1011 particles per 1 g of AAV-2 protein). hybridization of infected cell monolayers. Recently, this
Grimm et al and we have independently estimated that approach has been refined using stable rep expressing
cell lines and real time PCR detection of the amplifiedthe majority (80%) of vector particles in a rAAV prep-
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vector genomes [12, 23, 37]. (4) Finally, a transduction sequence homology between the rAAV vector and the
AAV helper plasmid were created [40, 41], and this has(expression) titer measures the number of virus particles
competent to infect and express the transgene in the greatly reduced or eliminated contaminating wild-type
AAV from rAAV vector stocks. Fortunately, stable celltarget cell. Although a common method, widely varying
titers (over three orders of magnitude) can be generated line production approaches do not appear to produce
detectable wild-type-like AAV [16, 20, 21]. To test vectorfrom the same vector stock by altering the target cell line
or the intracellular environment (e.g., concurrent helper stocks for replication competent AAV, 1% of the rAAV
stock should be used in a serial passage assay (typicallyadenovirus infection or cell confluency). Therefore, com-
parisons of rAAV efficacy in different target cells or on adenovirus-infected 293 or HeLa cells) to confirm
the absence of wild-type AAV replication intermediatesbetween vectors with different promoters become highly
suspect. How do these various titers relate to each other? (monomeric and dimeric forms) in DNA isolated from
the P2 cell population [16].Although each vector preparation will possess a specific
particle to infectivity ratio, an approximate ratio for hep-
Reprint requests to K. Reed Clark, Ph.D., Room W510, Children’s
arin purified particles can be roughly given as 2500 total Hospital, 700 Children’s Drive, Columbus, Ohio 43205.
E-mail: clarkr@pediatrics.ohio-state.eduparticles: 500 Dnase-resistant vector genome containing
particles: 10 replication units: 1 transduction unit. Ide-
ally, for each rAAV production method, the viral yields
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should be expressed in the form of infectious units per
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